← Advanced Biomed Inc. (ADVB) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Advanced Biomed Inc. (ADVB)
Services-Medical Laboratories · market cap $9M · as of 2026-07-22
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-18 (est.)
Earnings
Pipeline
12
programs
Upcoming events
2
next 90d+
Dossier
Ready
cached
Advanced Biomed Inc. (ADVB) is a micro-cap clinical-stage company (market cap ~$12M, ~1.38M shares at ~$8.90) operating across ophthalmology, neurology, and respiratory indications with a large pipeline of SPARC-branded and partnered assets. The lead near-term catalyst is a Phase 2 readout for Vodobatinib (K0706) capsules expected August 15, 2026, followed by a PDUFA date estimated December 18, 2026. The company carries only $2.6M in cash, implying a runway of roughly 5-6 months and an acute financing overhang.
The catalyst path
- 2026-11-18 (est.)Earningsimp 5/10
- 2026-12-18 (est.)PDUFAimp 8/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| Vodobatinib (K0706) capsules | Phase 2 | Healthy (For Part A) |
| SDN-037 | Phase 3 | Inflammation and Pain Associated With Ocular Surgery |
| Brimonidine Tartrate Ophthalmic Suspension | Phase 3 | Open Angle Glaucoma |
| SPARC1104 modified dose regimen I | Phase 3 | Spasticity |
| SPARC1103 low dose | Phase 2 | Spasticity |
| SPARC1203 | Phase 2 | Allergic Rhinitis |
| SPARC0913 | Phase 3 | Open Angle Glaucoma |
| SPARC1310 I | Phase 2 | Seasonal Allergic Rhinitis |
| SPARC0912 | Phase 3 | Open Angle Glaucoma |
| SPARC1316 Dose 1 | Phase 2 | Asthma |
| SPARC1102 I | Phase 2 | Allergic Conjunctivitis |
| SPARC0921 | Phase 3 | Spasticity |
Price & technical context
3-month
+35.3%
6-month
+50.8%
12-month
-23.4%
52-wk range
$3.71–$18.98
vs 50-day MA
-19.1%
vs 200-day MA
+10.8%
Realized vol
151.4%
Max drawdown
-95.4%
Daily closes through 2026-10-02. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for ADVB (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 12 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.